Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy
Cancer, 04/24/2012Defina M et al.
This study assessed for the first time the persistence of CD34+Ph+ cells during nilotinib first–line treatment. Preliminary results showed that in patients in CCyR, even after short–term nilotinib therapy, residual leukemic progenitors are very rarely detected compared with imatinib–treated CCyR patients.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.